Sagent Pharmaceuticals' Clindamycin Phosphate ANDA090108 Receives AP Status
Sagent Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Clindamycin Phosphate.
Company
Pharmaceutical intelligence for Sagent Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
The FDA has granted approval status (AP) for ANDA090109, a supplemental application for Clindamycin Phosphate by Sagent Pharmaceuticals.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.